Results 181 to 190 of about 26,552 (294)

Lobeglitazone and the risk of renal progression in Korean patients with type 2 diabetes mellitus: a retrospective cohort study. [PDF]

BMJ Open
Hong SH, Lee H, Lee SY, Sung YA, Hong YS, Song DK, Jung H, Kim MH.   +7 more
europepmc   +1 more source

Durability and Safety of Imeglimin as an Add‐On to DPP‐4 Inhibitors in Japanese Type 2 Diabetes: The 104‐Week FAMILIAR Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9101-9111, October 2026.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of imeglimin added to dipeptidyl peptidase‐4 (DPP‐4) inhibitors in Japanese patients with type 2 diabetes, focusing on glycemic durability and safety in elderly patients over 104 weeks. Materials and Methods This multicenter, randomized, placebo‐controlled trial comprised a 24‐week double ...
Masashi Shimoda, Takeshi Osonoi, Masahiro Iwamoto, Hideaki Kaneto, Kohei Kaku   +4 more
wiley   +1 more source

Comparative neuroprotective effects of antidiabetic medications on Parkinson's disease risk: a Bayesian network meta-analysis. [PDF]

J Glob Health
Lee SH, Rho Y, Lee S, Shin S, Choi YJ.
europepmc   +1 more source

Effectiveness of Telehealth Low‐Carbohydrate Intervention in Preventing Chronic Kidney Disease: A Real‐World, Retrospective, Matched Cohort Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9054-9068, October 2026.
ABSTRACT Background Lifestyle interventions targeting metabolic health may influence chronic kidney disease (CKD) risk, particularly among adults with type 2 diabetes and obesity. We evaluated real‐world associations between a telehealth‐delivered, individualized nutrition therapy program (VINT) and CKD incidence and progression compared with usual ...
Shaminie J. Athinarayanan, Petter Bjornstad, Priya V. Shanmugam, Thomas Weimbs, Adam J. Wolfberg, Jeff S. Volek, Jonathan Himmelfarb, Richard J. Johnson   +7 more
wiley   +1 more source

An Interesting Case of Sulphonylurea-Responsive Permanent Neonatal Diabetes Mellitus With Potassium Channel Mutation. [PDF]

Cureus
O'Connell K, Nadernejad C, Bupp C, Dewoolkar A.   +3 more
europepmc   +1 more source

Effect of Medications for Type 2 Diabetes on Cardiovascular Events and Mortality: A Comprehensive Pairwise and Network Meta‐Analysis

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9403-9411, October 2026.
ABSTRACT Aim To assess the effect of all the approved classes of medications for type 2 diabetes on Major Adverse Cardiovascular events (MACE) and all‐cause mortality. Methods We performed a pairwise and network meta‐analysis, including randomised controlled trials with a duration of at least 40 weeks, comparing medications versus placebo or an active ...
Giovanni Antonio Silverii, Valerio Velardi, Christian Marinelli, Antonino Lax, Matteo Monami, Edoardo Mannucci   +5 more
wiley   +1 more source

Impact of Albuminuria‐Lowering Treatments on Cardiovascular Predictive Ceramides in Diabetes: Post Hoc Analysis of the ROTATE Trials

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9346-9355, October 2026.
ABSTRACT Aim Cardiovascular disease (CVD) is the leading cause of mortality in individuals with diabetes. Diabetic kidney disease, closely related to CVD risk, is prevalent in up to 40% of this population. Emerging evidence suggests ceramide lipids as accurate biomarkers for CVD.
Kristina Pigsborg, Simon Maria Kienle, Asger Wretlind, Viktor Rotbain Curovic, Martin Bæk Blond, Hiddo J. L. Heerspink, Tine Willum Hansen, Frederik Persson, Karolina Sulek, Cristina Legido‐Quigley, Peter Rossing   +10 more
wiley   +1 more source

Deconstructing the Master Switch: Advances in Direct NLRP3 Inhibition. [PDF]

Pharmaceuticals (Basel)
Xu Y, Murphy S.
europepmc   +1 more source

Efficacy and Safety of Once‐Weekly Semaglutide 2.0 mg as an Add‐On to Dose‐Reduced Insulin Glargine versus Dose‐Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE)

Diabetes, Obesity and Metabolism, Volume 28, Issue 10, Page 9304-9316, October 2026.
ABSTRACT Aims Type 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once‐weekly semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine (Sema+IGlarreduced) versus dose‐titrated IGlar (IGlartitrated) on glycated haemoglobin (HbA1c), body weight (BW), daily insulin dose, and ...
Helena W. Rodbard, Concetta Irace, Jevitha Lobo, Konstantinos Makrilakis, Prachi Priyadarshini, Suvanjaa Sivalingam, Santiago Tofé Povedano, Anuj Bhargava   +7 more
wiley   +1 more source

KCNJ11-associated infantile epileptic spasms syndrome and neonatal diabetes. [PDF]

Epileptic Disord
Gonzalez BJ, Juanes M, Touzon MS, Alonso C, Obregon Gomez LR, Moreno N, Prieto M, Persico AL, Valenzuela GR, Caraballo R.   +9 more
europepmc   +1 more source